Abstract
109 Phase I trial of a new anti-cytomegalovirus agent, (s)-1[3-hydroxy-2-(phosphonyl-methoxy)propyl]cytosine (HPMPC), in HIV-infected volunteers: M Wachsman, BG Petty, HS Jaffe, K Cundy, P Fisher, and PS Lietman. The Johns Hopkins University School of Medicine, Baltimore, MD, and Gilead Sciences, Inc., Foster City, CA, USA
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.